Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | CBL |
| Variant | W802* |
| Impact List | nonsense |
| Protein Effect | loss of function - predicted |
| Gene Variant Descriptions | CBL W802* results in a premature truncation of the Cbl protein at amino acid 802 of 906 (UniProt.org). W802* has not been characterized however, due to the effects of other truncation mutations downstream of W802 (PMID: 23744067), is predicted to lead to a loss of Cbl protein function. |
| Associated Drug Resistance | |
| Category Variants Paths |
CBL mutant CBL inact mut CBL W802* |
| Transcript | NM_005188.4 |
| gDNA | chr11:g.119298511G>A |
| cDNA | c.2405G>A |
| Protein | p.W802* |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_005188 | chr11:g.119298511G>A | c.2405G>A | p.W802* | RefSeq | GRCh38/hg38 |
| NM_005188.4 | chr11:g.119298511G>A | c.2405G>A | p.W802* | RefSeq | GRCh38/hg38 |
| NM_005188.3 | chr11:g.119298511G>A | c.2405G>A | p.W802* | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CBL mutant | myelofibrosis | not applicable | N/A | Guideline | Prognostic | CBL mutations are associated with inferior overall survival in patients with primary myelofibrosis (NCCN.org). | detail... |
| CBL mutant | myelodysplastic/myeloproliferative neoplasm | not applicable | N/A | Clinical Study | Prognostic | In clinical analyses, mutations in CBL were associated with adverse prognosis in patients with chronic myelomonocytic leukemia (PMID: 26230957, PMID: 23690417, PMID: 19901108). | 26230957 19901108 23690417 |
| CBL mutant | bone marrow cancer | sensitive | Quizartinib | Preclinical | Actionable | In a preclinical study, Vanflyta (quizartinib) reduced white blood cell counts and decreased myeloid cell invasion in a CBL mutant mouse model with myeloproliferative disorder (PMID: 22990016). | 22990016 |
| CBL mutant | systemic mastocytosis | not applicable | N/A | Guideline | Prognostic | CBL mutations are associated with an adverse prognosis in patients with systemic mastocytosis (NCCN.org). | detail... |